RIOX1抗体;RIOX1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P12979(RIOX1 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P12979(RIOX1 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

The RIOX1 (Ribosomal Oxygenase 1. also known as NO66 or MAPJD) antibody targets a protein belonging to the JmjC domain-containing dioxygenase family. RIOX1 functions as a histone demethylase, specifically removing methyl groups from histone H3 lysine 36 (H3K36me3/me2) and H4 lysine 20 (H4K20me3), thereby regulating chromatin structure and gene expression. It plays roles in ribosomal RNA biogenesis, cellular oxygen sensing, and epigenetic regulation. Studies link RIOX1 to diverse biological processes, including osteoblast differentiation, cell cycle control, and tumorigenesis. Dysregulation of RIOX1 has been implicated in cancers (e.g., colorectal, breast), developmental disorders, and bone metabolism abnormalities.

RIOX1 antibodies are widely used in research to investigate its expression patterns, subcellular localization (nucleolar and nuclear), and interactions in both normal and pathological states. Commercial RIOX1 antibodies are available for applications such as Western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). Validation data, including knockout controls, are critical due to potential cross-reactivity with related JmjC proteins. Recent studies emphasize its role in hypoxia adaptation and metabolic reprogramming, positioning RIOX1 as a potential therapeutic target. Researchers frequently utilize these antibodies to explore its dual enzymatic activity in histone demethylation and ribosomal oxygen sensing pathways.